Table 3.

Subgroup analysis of risk of AMD among sildenafil users and non-users

	Sildenafil use		Non-sildenafil use		Crude HR (95% CI)	P value	Adjusted HR (95% CI)	P value
	Patients with ED, n	AMD, n (%)	Patients with ED, n	AMD, n (%)
Age, years
40–49	4336	10 (0.2)	8404	9 (0.1)	1.76 (0.73 to 4.24)	0.205	1.18 (0.47 to 2.92)	0.728
50–59	10 092	39 (0.4)	19 922	63 (0.3)	1.10 (0.74 to 1.65)	0.936	0.93 (0.61 to 1.40)	0.717
60–69	11 463	77 (0.7)	22 641	154 (0.7)	0.87 (0.66 to 1.14)	0.301	0.80 (0.60 to 1.05)	0.108
70–79	5151	89 (1.8)	10 124	139 (1.4)	1.15 (0.88 to 1.49)	0.311	1.14 (0.87 to 1.49)	0.336
Over 80	533	19 (3.7)	1064	33 (3.2)	1.07 (0.60 to 1.90)	0.816	0.96 (0.54 to 1.72)	0.896
Type 2 diabetes status
With diabetes	10 794	127 (1.2)	19 486	148 (0.8)	1.06 (0.83 to 1.35)	0.616	1.20 (0.94 to 1.53)	0.144
Without diabetes	20 781	107 (0.5)	42 669	250 (0.6)	0.86 (0.69 to 1.08)	0.207	0.82 (0.65 to 1.02)	0.078
Index date prior to 2018	28 274	229 (0.81)	55 636	393 (0.71)	1.01 (0.86 to 1.19)	0.876	0.98 (0.83 to 1.15)	0.776

AMD, age-related macular degeneration; ED, erectile dysfunction.